CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05,...
Hence then, the article about the results of phase iii optitrop lung05 study of sacituzumab tirumotecan sac tmt presented as an asco oral presentation and simultaneously published in the lancet was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet )
Also on site :
- Airwallex Challenges Legacy Software With New Billing Solution .. PYMNTS.com
- ‘The Birds’ Limited Series Starring Sarah Snook Hits TV Marketplace; New Take On Hitchcock’s Classic Comes From Tom Spezialy, David Heyman & UIS
- Not the finest hour: BBC slammed over Churchill and Gandhi deepfakes (VIDEO)